Quantifying the Benefits of Digital Biomarkers in Pharma

The pharmaceutical industry faces a constant challenge: demonstrating the true value of innovative solutions. With the rise of connected sensor technologies, and wearable devices that can offer objective, continuous patient measurements, healthcare stakeholders are presented with a wealth of opportunities to innovate how we measure health. In particular, digital biomarkers have emerged as potential game-changers within drug development. Yet, the journey to their full-scale implementation is challenging and pharma has but cautiously adopted digital biomarkers in R&D.
Join this roundtable to discuss how we can surmount the current scepticism surrounding digital endpoints, including digital biomarkers. With your peers you’ll tackle the following questions:

• What are the proof points pharma requires to deploy digital biomarkers and endpoints with greater confidence?
• What are the quantifiable benefits of leveraging technology-enabled measurements in drug development? Who is leading the charge?
• What are the cost-benefit considerations associated with integrating digital biomarkers into the pharmaceutical R&D process?
• What are the greatest barriers to adoption of technology-enabled measurements and how can we as an industry come together to overcome the biggest obstacles?